Great news from The Christie NHS Foundation Trust:

The STAMPEDE trial, the world’s largest prostate cancer intervention study with nearly 12,000 participants, has shown that metformin can reduce hormone therapy side effects in advanced prostate cancer treatment.

Patients taking metformin alongside standard therapy experienced significantly less weight gain, lower blood sugar levels, and reduced harmful fats compared to those on standard therapy alone.

Professor Noel Clarke, a principal investigator and urologist at the trust, highlighted the trial’s transformative impact on clinical practice, noting the potential for metformin to improve patients’ health and quality of life while calling for its rapid adoption in NHS treatment protocols.

Read the full LinkedIn post - https://www.linkedin.com/posts/the-christie-nhs-foundation-trust_the-stampede-trial-has-recruited-nearly-12000-activity-7271916014487937025-VOzL?utm_source=share&utm_medium=member_desktop